We've been recommending gold shares for months now, ever since prices collapsed in April. But timing's getting critical, because now the market is telling you gold is set to surge...
The first piece of evidence hit my radar on August 1st, moments after Barrick Gold released its $8.7 billion "news." (More on that in a minute.)
The Commitment of Traders report - perhaps the best leading indicator for gold prices - delivered the second piece of evidence: a staggering 70% spike in "red flag" futures trading. And the third and fourth pieces of evidence just arrived.
But before we look at each of these events in detail, here's what you need to know:
Any one of these indicators is bullish on its own. So when all four signals flash at once, please don't wait.
A "Gold Convergence" like this hasn't happened in 12 years...
Indicator No. 1: A True Bottom
Calling market bottoms - and tops, for that matter - is typically a 50/50 proposition... unless, of course, the market hands you an overwhelming element of proof, just like it did on August 1st...
Rent-A-Center, Inc., together with its subsidiaries, primarily engages in leasing household durable goods to customers on a rent-to-own basis. The company?s stores offer durable products, such as consumer electronics, appliances, computers, and furniture and accessories under flexible rental purchase agreements that allow the customer to obtain ownership of the merchandise at the conclusion of an agreed upon rental period. It also provides merchandise on an installment sales basis in its stores. As of December 31, 2010, the company operated 3,008 company-owned stores in the United States, and in Canada, Puerto Rico, and Mexico, including 42 retail installment sales stores under the names ?Get It Now? and ?Home Choice?; and 18 rent-to-own stores located in Canada under the ?Rent-A-Centre? name. It also operates 209 franchised rent-to-own stores in 32 states under the ColorTyme trade name; and 384 kiosk locations under the ?RAC Acceptance? model. In addition, the company, th rough its ColorTyme?s franchised stores, offers custom rims and tires for sale or rental under the trade names ?RimTyme? or ?ColorTyme Custom Wheels?. Rent-A-Center, Inc. was founded in 1986 and is headquartered in Plano, Texas.
Advisors' Opinion: - [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Rent-A-Center (NASDAQ: RCII) were down 21.51 percent to $24.51 on Q4 results.
Apple (NASDAQ: AAPL) shares tumbled 7.80 percent to $507.55 after the company issued weak sales forecast for the second quarter and reported downbeat holiday iPhone sales.
- [By Marc Bastow]
Rent-to-own consumer products company Rent-A-Center (RCII) raised its quarterly dividend 10% to 23 cents per share, payable on Jan. 23 to shareholders of record as of Jan. 3.
RCII Dividend Yield: 2.77%
- [By Garrett Cook]
Rent-A-Center (NASDAQ: RCII) shares tumbled 11.22 percent to $25.80 after the company issued a downbeat guidance for the second quarter. The company expected adjusted earnings of $0.36 to $0.38 per share on revenue of around $773 million.
- [By Lisa Levin]
Rent-A-Center (NASDAQ: RCII) shares slipped 10.98% to $25.87 after the company issued a downbeat guidance for the second quarter. The company expected adjusted earnings of $0.36 to $0.38 per share on revenue of around $773 million.
10 Best Forestry Stocks To Buy Right Now: Nikon Corp (NINOY)
NIKON CORPORATION is a Japan-based company mainly engaged in the manufacture and sale of optical products. The Company is active in four business segments. The Precision Apparatus segment offers semiconductor exposure apparatus and liquid crystal (LC) exposure apparatus. The image segment provides digital cameras, film cameras and interchangeable lens. The Instruments segment offers microscopes, measuring machines and semiconductor inspection equipment. The Others segment provides glass materials, telescopes, glasses and survey airplanes.
As of August 19, 2009, the Company held a 92.17% stake in Metis NV. The Company has 65 subsidiaries and 10 associated companies in the country and overseas markets.
Advisors' Opinion: - [By Dan Carroll]
Unfortunately, the yen's impact on stocks has blurred the lines on investments. Look no further than down-on-its-luck camera maker Nikon (NASDAQOTH: NINOY ) . Nikon's shares gained more than 8% over the past week due to the yen's weakness, as the company rakes in more than a quarter of its sales in Europe. Still, the stock's lost more than 43% year to date.
10 Best Forestry Stocks To Buy Right Now: First Trust Dow Jones Internet Index Fund (FDN)
First Trust Dow Jones Internet Index Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Dow Jones Internet Composite Index (the Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index represents companies that generate the majority of their revenues via the Internet. The Index aims to represent 80% of the float-adjusted Internet equity universe. The Index contains two sub-indexes, the Dow Jones Internet Commerce Index and the Dow Jones Internet Services Index. For its stock to be eligible for the universe, a company must generate at least 50% of annual sales/revenues from the Internet, and be included in the Dow Jones U.S. Index. The Fund�� investment advisor is First Trust Advisors L.P.
Advisors' Opinion: - [By MONEYMORNING.COM]
That's where the First Trust Dow Jones Internet Index (NYSE Arca: FDN) comes in.
Besides Facebook, which is its largest holding, FDN also owns Amazon.com (Nasdaq: AMZN) and both classes of Google Inc. (Nasdaq: GOOGL), which has voting rights, and GOOG, which does not.
10 Best Forestry Stocks To Buy Right Now: Novartis AG (NVS)
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon's portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.
Pharmaceuticals Division
The Company�� Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented prescription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company�� Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.
The Company�� Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company�� Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson's disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.
Alcon Division
The Company�� Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon's Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon Division's Ophthalmic Pharmaceuticals business combines Alcon's range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division's Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav solution for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.
Sandoz Division
The Company�� Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women's health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals' Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company�� Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world's blood supply. Novartis Vaccines' products include influenza, meningococcal, pediatric, adult and travel vaccines.
The Company�� influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines include Polioral and Quinvaxem.
Consumer Health
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for companion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.
Advisors' Opinion: - [By MONEYMORNING.COM]
One caveat: Big pharma Novartis AG (NYSE: NVS) and a start-up biotech called Juno Therapeutics (at present privately held) are currently wrangling for the intellectual rights to this technology. When the dust settles, put your money on the winner.
- [By Tim Brugger]
The Food and Drug Administration has granted Switzerland-based Novartis (NYSE: NVS ) its "Breakthrough Therapy" (BT) designation for Novartis' acute heart failure (AHF) treatment RLX030 (serelaxin), the company announced today.
- [By Ben Levisohn]
According to Bloomberg, Novartis (NVS) has dropped out of the bidding for the high flying biotech stock on account of its high price tag:
Novartis AG is out of the bidding for Onyx Pharmaceuticals Inc., according to a person familiar with the situation.
- [By Markus Aarnio]
Companies working on chemically synthesized siRNAs include Merck (MRK), through its subsidiary Sirna Therapeutics, Inc., Novartis (NVS), Takeda (TKPHF.PK), Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira (TKMR), Sylentis and Dicerna Pharmaceuticals, Inc.
10 Best Forestry Stocks To Buy Right Now: The Middleby Corporation (MIDD)
The Middleby Corporation, through its subsidiaries, engages in the design, manufacture, and sale of commercial foodservice and food processing equipment in the United States, Canada, Asia, Europe, the Middle East, and Latin America. The company?s Commercial Foodservice Equipment Group segment manufactures cooking equipment for restaurants and institutional kitchens. Its product line comprises conveyor ovens, ranges, steamers, convection ovens, combi-ovens, broilers and steam cooking equipment, induction cooking systems, baking and proofing ovens, griddles, char broilers, catering equipment, fryers, toasters, hot food servers, food warming equipment, and coffee and beverage dispensing equipment. These products are sold and marketed under the brand names of Anets, Blodgett, Blodgett Combi, Blodgett Range, Bloomfield, CTX, Carter-Hoffmann, CookTek, Doyon, Frifri, Giga, Holman, Houno, Jade, Lang, MagiKitch?n, Middleby Marshall, Nu-Vu, Pitco, PerfectFry, Southbend, Star, Toastm aster, TurboChef, and Wells. In addition, this segment involves in sales, distribution, and export management activities internationally through independent manufacturing representatives and a combined network of independent and company-owned distributors. The Middleby?s Food Processing Equipment Group segment manufactures preparation, cooking, packaging, and food safety equipment for the food processing industry. Its principal products include batch ovens, belt ovens, and conveyorized cooking systems sold under the Alkar brand name; grinding, slicing, emulsification, mixing, and blending products under the Cozzini brand name; breading, battering, mixing, slicing, and forming equipment sold under the MP Equipment brand name; and packaging and food safety equipment sold under the RapidPak brand name. The company was formerly known as Middleby Marshall Oven Company and changed its name to The Middleby Corporation in 1985. The Middleby Corporation was founded in 1888 and is bas ed in Elgin, Illinois.
Advisors' Opinion: - [By Jim Jubak]
And a few attractive names are down even more. Schlumberger (SLB), for instance, is down 7.1% from November 11 through December 4, and Middleby (MIDD) is down 8.8% from October 25 through December 4.
- [By Lawrence Meyers]
Diller then spins off some of these entities into public companies, as he did with Home Shopping Network (HSNI) and timeshare company Interval Leisure Group (IILG). The company�� 52 week high was $80.64, it trades right now at $66. I�� love to make this one of my stocks to buy in the below the $50 mark, but IACI would be a bargain under $55.
Middleby Corporation (MIDD) Middleby Corporation (MIDD) started as an oven company in 1888. Over its history, it has expanded into a global food service, processing, and residential kitchen equipment manufacturer and distributor.
- [By Chris Hill]
Molex (NASDAQ: MOLX ) is up big after Koch Industries agreed to buy the company for $7.2 billion in cash. Yum! Brands' (NYSE: YUM ) same-store sales in China fall 10% in August. Caterpillar (NYSE: CAT ) shares are up on news that China's exports grew more than 7% in August. And Middleby (NASDAQ: MIDD ) closes in on a new all-time high. In this segment, the guys discuss four stocks making big moves.
10 Best Forestry Stocks To Buy Right Now: MER Telemanagement Solutions Ltd.(MTSL)
Mer Telemanagement Solutions Ltd., together with its subsidiaries, designs, develops, markets, and supports a line of telecommunication expense management (TEM), and customer care and billing solutions for business organizations and other enterprises worldwide. Its TEM solutions assist enterprises and organizations in the allocation of costs, budget control, fraud detection, processing of payments, and spending forecasting. The company also offers converged billing solutions, including applications for charging and invoicing customers, interconnect billing, and partner revenue management through pre-pay and post-pay schemes for wireless providers, voice over Internet protocol, Internet protocol television, and content service providers. Its products provide telecommunication and information technology managers with tools to reduce communication costs, recover charges payable by third parties, and to detect and prevent abuse and misuse of telephone networks comprising fault telecommunication usage. The company markets its products through its direct sales force, distributors, and business telephone switching systems manufacturers and vendors. Mer Telemanagement Solutions Ltd. was founded in 1995 and is headquartered in Raanana, Israel.
Advisors' Opinion: - [By Bryan Murphy]
If you're a small cap enthusiast looking for some budding ideas, you may not need to look any further than China GengSheng Minerals, Inc. (NYSEMKT:CHGS), Bio Matrix Scientific Group Inc. (OTCMKTS:BMSN), and MER Telemanagement Solutions Ltd. (NASDAQ:MTSL). All three have either pushed themselves to the brink of a breakout, if they haven't started one already. Here's a closer technical look at MTSL, BMSN, and CHGS, and what it's going to take to get them going if they're not going already.
- [By James E. Brumley]
Trading can be a quirky game sometimes. Most of the time, news - or at least loudly voiced opinions - tend to result from or be the cause of a fast-moving stock. Every now and then though, as in the case with MER Telemanagement Solutions Ltd. (NASDAQ:MTSL), a stock can build up steam with little to no news linked to that move. That doesn't make that stock a poor pick, however. Indeed, MTSL looks like it's turning into a homerun, and that alone is worth a look.... and maybe even worth a shot.
10 Best Forestry Stocks To Buy Right Now: Six Flags Entertainment Corporation New(SIX)
Six Flags Entertainment Corporation owns and operates regional theme, water, and zoological parks. The company?s parks offers various selection of state-of-the-art and traditional thrill rides, water attractions, themed areas, concerts and shows, restaurants, game venues, and retail outlets. It owns and operates 19 parks, including 17 parks in the United States; 1 park in Mexico City, Mexico; and 1 park in Montreal, Canada. The company was formerly known as Six Flags, Inc. and changed its name to Six Flags Entertainment Corporation in April 2010. Six Flags Entertainment Corporation was founded in 1971 and is based in Grand Prairie, Texas.
Advisors' Opinion: